This month
The February head-to-head loss that defined the narrative — and the May data that reframed it
On February 23, 2026, Novo Nordisk released results from the REDEFINE 4 trial — the head-to-head comparison between CagriSema and Lilly's tirzepatide (Zepbound) — and the market had a rough morning. CagriSema, the fixed-dose combination of cagrilintide and semaglutide, produced approximately 23% average weight loss at 84 weeks. Tirzepatide produced roughly 25%. The primary endpoint was non-inferiority. It was not demonstrated. [STAT News](https://www.statnews.com/2026/02/23/novo-nordisk-cagrisema-fail-comparison-trial-zepbound-eli-lilly-obesity/) reported the stock fell roughly 15% that day. The narrative that settled in was clean: CagriSema lost. Then, on May 12, 2026, Novo Nordisk presented a new REDEFINE-1 analysis at the 33rd European Congress on Obesity in Istanbul — and a different question entered the room. In CagriSema-treated participants who achieved 30% or more total body weight loss, fat mass proportion fell from 46.3% to 33.2%. Lean soft tissue proportion rose from 51.3% to 63.2%. Muscle strength, measured by sit-to-stand testing, did not decline relative to placebo. The dominant metric in obesity medicine is total weight lost. These numbers are about what that weight is made of — which is a clinically distinct argument, and one the February narrative made no room for.
The actual biology
Amylin is not GLP-1, and the mechanism story is why cagrilintide exists as a separate drug
Cagrilintide is a long-acting amylin analog. Amylin is a peptide hormone co-secreted alongside insulin by pancreatic beta cells after eating — and it is not glucagon-like peptide-1. The two are different molecules acting on different receptors with meaningfully different downstream profiles. GLP-1 receptor agonists like semaglutide work largely through the gut-brain axis via GLP-1 receptors expressed across multiple systems, slowing gastric emptying and suppressing appetite through several converging signals. Amylin works through amylin receptors concentrated in the area postrema — a brainstem nucleus involved in satiety and nausea sensitivity — and independently modulates glucagon secretion. The case for combining them is complementary mechanism logic: two physiologically distinct satiety levers, each engaging a different input, potentially additive in effect. Cagrilintide is engineered for once-weekly subcutaneous dosing through fatty acid modifications that extend its half-life, the same structural strategy Novo Nordisk used to make semaglutide a weekly drug. The [PubMed literature on cagrilintide](https://pubmed.ncbi.nlm.nih.gov/?term=cagrilintide) documents where the mechanism research and Phase 2 dose-finding studies go before the REDEFINE program began. Amylin analogs are not a new category — pramlintide, an earlier amylin analog, received FDA approval for diabetes management — but a long-acting once-weekly version engineered specifically for obesity at this clinical scale represents a meaningfully different ambition.
What the internet says
The next-generation obesity frame sells faster than the amylin mechanism can travel
The public story around CagriSema usually starts and ends with one number: 22.7%. That is the mean weight loss from the REDEFINE 1 trial, published in the [New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa2502081), comparing CagriSema against semaglutide alone, cagrilintide alone, and placebo across 68 weeks. That number is real, it comes from a large randomized trial, and it is legitimately striking. What the coverage consistently omits is the comparison context: semaglutide alone in the same trial produced 14.9% weight loss; cagrilintide alone produced 11.8%. The combination benefit is meaningful and statistically significant, but understanding it requires knowing what each component contributed and how much the amylin layer added. The dominant cultural shorthand — the next-generation obesity drug that beats Ozempic — does not include the amylin mechanism, does not include the REDEFINE 4 competitive result, and does not include the fact that CagriSema is not yet approved. Novo Nordisk filed a New Drug Application with the FDA in December 2025. The expected review window closes around October 2026. Until that decision, the drug that produces 22.7% weight loss cannot be prescribed under normal channels — a gap the FDA has explicitly warned about in the broader context of unapproved GLP-1 and peptide products marketed for weight loss.
What the data actually shows
REDEFINE 1 established the signal, REDEFINE 4 tested the ceiling, and Istanbul asked a third question
The REDEFINE program is structured to answer multiple distinct questions. REDEFINE 1 (3,417 participants, 68 weeks) established efficacy against components and placebo — the data now published in the NEJM. REDEFINE 4 (84 weeks) tested competitive positioning directly against tirzepatide, and as [BioPharma Dive reported](https://www.biopharmadive.com/news/novo-nordisk-cagrisema-zepbound-head-to-head-results/812810/) in detail, CagriSema did not demonstrate non-inferiority at the tested tirzepatide dose. That is the current ceiling for the competitive argument as of May 2026. The ECO 2026 analysis from May 12 asked something REDEFINE 4 was not designed to answer: what kind of weight loss? The DXA-measured body composition data — fat mass declining from 46.3% to 33.2%, lean soft tissue rising from 51.3% to 63.2% in the highest-loss cohort — carries clinical relevance beyond the percentage headline. Sarcopenic obesity, the condition in which excess fat and insufficient muscle coexist, is a real clinical concern, and a persistent question about aggressive pharmacologic weight loss is whether meaningful muscle loss accompanies it. The body composition signal from Istanbul argues that the amylin mechanism may contribute something the GLP-1-only comparison cannot fully capture. The [ClinicalTrials.gov registry for cagrilintide](https://clinicaltrials.gov/search?term=cagrilintide) shows the full scope of REDEFINE studies and the separate RENEW monotherapy program that Novo Nordisk is advancing based on cagrilintide's 11.8% standalone result.
Early human evidence
A real trial record in a drug that is not approved yet — and a muscle argument heading into October
Cagrilintide carries the Early human evidence tier on PeptideFactCheck. That classification does not dismiss the REDEFINE trials — these are large, peer-reviewed, randomized controlled studies with real human participants and clinically meaningful endpoints, not forum posts or vendor claims. What the tier reflects is that the drug is not approved, the full labeling does not exist, and the FDA review expected to conclude around October 2026 will determine the clinical context within which any authorization might exist. Early human means: interesting enough to watch, too early for broad certainty. That positioning is accurate for where cagrilintide sits in May 2026. The February REDEFINE 4 result defined the competitive narrative for the months since. The May body composition data from Istanbul is the counter-argument Novo Nordisk is now constructing — that CagriSema and tirzepatide may be better understood not as direct competitors where one wins by two percentage points, but as drugs with different mechanism profiles producing different kinds of weight loss outcomes. Whether that argument lands with FDA reviewers, prescribers, or payers is an open question. The October decision window will produce the first formal answer.
Editorial boundary
What this page will not do
It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.